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Abstract
 
Introduction
Disparities  in  enrollment  of  adults  in  cancer  clinical 
trials are well documented, but little is known about the 
attention given to this topic in comprehensive cancer con-
trol (CCC) plans. We assessed the extent to which CCC 
plans  address  disparities  in  clinical  trials  and  whether 
jurisdictions whose plans address disparities also mandate 
third-party reimbursement for clinical trial participation.
 
Methods
We  analyzed  57  CCC  plans  identified  from  Cancer 
PLANET (Plan, Link, Act, Network with Evidence-based 
Tools) and Cancerplan.org from April through December 
2007. We searched plans for general and disparity-specific 
content regarding clinical trials and analyzed the content 
for emergent themes. We assessed frequencies of themes, 
patterns between themes, and patterns between themes 
and laws. We reviewed third-party reimbursement laws, 
as of September 2007, as recorded by the National Cancer 
Institute’s State Cancer Legislative Database.
 
Results
Fifty-five (96%) CCC plans had content regarding clini-
cal trials. Of the 39 (71%) plans that specifically addressed 
disparities, 13 (33%) were in a state with laws mandating 
third-party reimbursement. Increasing participation and 
education, awareness, and outreach were the most com-
mon themes identified.
 
Conclusion
Although many CCC plans address disparities in clini-
cal trials, few of those plans are in jurisdictions that have 
third-party reimbursement laws.
Introduction
 
Knowledge gained through clinical trials has been critical 
to preventing, diagnosing, and treating cancer. However, 
not all cancer patients benefit equally from these improve-
ments. Nationally, 3% to 5% of adult cancer patients par-
ticipate in cancer clinical trials (1). Racial/ethnic minorities 
have represented less than 15% of all adult participants in 
National Cancer Institute (NCI) treatment trials (2), and 
a review of Food and Drug Administration (FDA) cancer 
trials found that adults aged 65 years or older represented 
barely one-third of clinical trial participants, even though 
they  account  for  approximately  60%  of  cancer  cases  in 
adults (3). Other adult populations, such as those living 
in rural areas (4), those who are low income (5), or those 
without health insurance or third-party reimbursement for 
clinical trials (5), are also less likely to participate.
 
Participants  in  clinical  trials  should  reflect  the  pop-
ulations  affected  by  the  particular  diagnosis  (6). 
Underrepresentation  in  clinical  trials  results  in  dispar-
ity in favor of participants who benefit from those trials. 
From  a  scientific  perspective,  diverse  representation  is 
necessary to test for differences in outcomes and to ensure 
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the  safety  of  therapies  across  a  range  of  biological  and 
genetic characteristics (6). From an ethical viewpoint, dis-
tributive justice requires that both the benefits and risks 
associated with clinical trial research be fairly distributed 
among those who are potentially affected (7). The goals 
in  addressing  disparities  in  clinical  trial  participation 
should be not only attaining representative participation 
among all groups of potential cancer patients but also fair 
opportunity to be aware of and participate in clinical trials 
without financial considerations.
 
The National Institutes of Health (NIH) and FDA man-
date the inclusion of women and minorities in clinical tri-
als (8,9). However, researchers have documented barriers 
to participating in cancer clinical trials. Barriers include 
lack of awareness (10), lack of being invited or recruited 
to  participate  (11),  eligibility  criteria  that  may  exclude 
certain groups (12), fear or mistrust of the medical and 
scientific community, and cultural barriers (eg, language, 
beliefs, attitudes) (11). In health care systems, physicians 
may not refer older patients to clinical trials because of 
concern about toxicity or side effects from the treatment 
(1) and may exclude patients because of their own preju-
dices (13). At a policy level, barriers may include the lack 
of state mandates for insurance coverage for clinical trials 
and the lack of appropriate enforcement and oversight of 
existing mandates (6).
 
Because  barriers  to  and  disparities  in  cancer  clinical 
trial  participation  exist  on  multiple  levels,  addressing 
these  issues  requires  a  comprehensive  approach.  One 
such  approach  is  reflected  in  the  comprehensive  cancer 
control (CCC) plan for each state, tribe, territory, or other 
jurisdiction. The CCC plan approach helps prevent duplica-
tion of effort, reduce gaps in interventions, and enhance 
existing  programs  by  coordinating  and  integrating  com-
munity resources within a given state, tribe, territory, or 
other jurisdiction (14). Through the CCC planning process, 
various stakeholders, including those representing health 
departments, national organizations, universities, and local 
organizations,  are  brought  into  a  statewide  coalition  to 
agree to local priorities and goals and to promote the plan 
among the stakeholders. These plans provide a basic, initial 
indicator of how each jurisdiction proposes to address their 
particular burden of cancer, including addressing dispari-
ties in cancer clinical trials. We describe the extent to which 
existing CCC plans address disparities in clinical trials and, 
of the plans that do address the issue, which ones come from 
jurisdictions with third-party reimbursement laws.
Methods
Data sources and collection
 
From  April  through  December  2007,  we  analyzed 
CCC  plans  available  on  the  Web  sites  Cancer  Control 
PLANET (Plan, Link, Act, Network with Evidence-based 
Tools)  (cancercontrolplanet.cancer.gov/state_plans.jsp) 
and  CancerPlan.org  (www.cancerplan.org).  Sponsored 
by  federal  and  national  organizations,  Cancer  Control 
PLANET is a Web portal designed to provide public health   
professionals with access to data and resources to design, 
implement,  and  evaluate  evidence-based  cancer  control 
programs  and  plans.  The  Web  portal  includes  links 
to  state-specific  cancer  incidence  and  mortality  rates, 
research-tested  intervention  products,  and  CCC  plans. 
Similarly, the Cancerplan.org Web site — a collaborative 
effort of the Centers for Disease Control and Prevention 
(CDC), American Cancer Society, and NCI — was devel-
oped to help states and other jurisdictions develop, imple-
ment, and evaluate their respective CCC plans by sharing 
best practices, resources, and tools. As a follow-up step, we 
conducted a keyword search via the Internet search engine 
Google in February 2008 to ensure that we had retrieved 
the most recent CCC plans in our initial search.
 
From  Cancer  Control  PLANET  and  CancerPlan.org, 
we identified 57 CCC plans; the Internet search identi-
fied updates to 6 of them. All CCC plans were in Adobe 
Acrobat Portable Document Format (.pdf) (Adobe Systems, 
Inc,  San  Jose,  California),  which  allowed  us  to  search 
each  plan  using  keywords.  Our  search  strategy  was  a 
2-step  process.  In  step  1,  we  identified  the  CCC  plans 
that  addressed  clinical  trials  by  searching  for  “clinical 
trial(s),” “randomized trial(s),” “clinical research,” “treat-
ment trial(s),” “investigational therapy,” or “experimental 
treatment.” This search strategy was based on terms used 
in a previous study (15). We identified 55 of the initial 
57  CCC  plans  as  including  goals,  objectives,  strategies, 
or actions relevant to clinical trials. From these 55 CCC 
plans, we extracted the relevant text verbatim. We did 
not extract text from a plan’s introduction, background, or 
other purely narrative sections.
 In  step  2,  we  identified  the  plans  that  specifically 
addressed disparities related to clinical trials. We devel-
oped a disparity-specific keyword search strategy based 
on terms from the existing literature (12) and a randomly 
selected sample of 5 CCC plans. Four plans from tribes or VOLUME 6: NO. 4
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territories  were  deemed  automatically  relevant  because 
of  their  specific  focus  on  underrepresented  populations. 
We  searched  the  remaining  51  plans  identified  by  step 
1  for  the  terms  “disparities/disparity,”  “underserved,” 
“high-risk,”  “underrepresented,”  “culture/cultural,”  “lan-
guage,”  “linguistic,”  “low-income,”  “diverse/diversity,” 
“underprivileged,” “rural,” “elderly,” “older adults,” “aged,”   
“disadvantaged,”  “uninsured,”  “race/racial,”  “ethnic,” 
“minority/minorities,”  “black/African  American,”  “His-
panic,”  “American  Indian/Native  American,”  “Asian,”  or 
“tribe/tribal,” and extracted the relevant text verbatim.
 
We  used  NCI’s  State  Cancer  Legislative  Database 
(SCLD) to determine which states had mandatory cover-
age laws for third-party reimbursement (16). The SCLD 
is a searchable database of synthesized information from 
enacted  state  laws  and  resolutions  that  address  cancer 
control topics.
Analysis plan
 
We analyzed the extracted text using an inductive and 
iterative approach to identify emergent themes (17). Each 
author  independently  reviewed  the  extracted  texts  and 
categorized the data into themes. We then compared pro-
posed themes and used a constant comparison process to 
define and refine the themes. Final decisions were reached 
by the consensus of all authors.
 
We conducted a frequency count of each theme, analyzed 
the relationship patterns between themes, and examined 
the  patterns  between  themes  and  third-party  coverage 
laws. We read the goals, strategies, and objectives sections 
of the plans that addressed clinical trial disparities to see 
whether they focused on specific cancers or specific popula-
tions, and then recorded our results.
Results
Summary of CCC plans
 
The  CCC  plans’  starting  dates  ranged  from  2001  to 
2007, and the ending dates ranged from 2004 to 2011. All 
but 2 of the 57 plans proposed goals, objectives, strategies, 
or actions related to clinical trials in general. Among the 
55 plans mentioning clinical trials, 39 (71%) specifically 
addressed disparities in participation. No pattern appeared 
to exist between the dates of the plans and whether they 
addressed  the  subject  of  disparities.  Of  the  55  jurisdic-
tions represented by the plans, 20 (35%) had some type of 
third-party reimbursement law, which varied for different 
types of insurers and phases of clinical trials. Coverage 
for clinical trial participation was mandatory in 19 of the 
20 jurisdictions, and 1 prohibited exclusion of coverage for 
clinical trials. Nine of the states without reimbursement 
laws but with CCC plans addressing disparities advocated 
for some level of insurance coverage or reimbursement for 
clinical trial participation from private or public insurers 
or both in their plans.
Disparity-specific CCC plans
 
We derived 10 main themes from the 39 plans dealing 
with clinical trial disparities (Table 1) and an 11th “other” 
category for subjects addressed by only 1 plan. The other 
category included topics such as the need to expand clini-
cal  trial  infrastructure,  to  develop  continuing  education 
resources on clinical trials, and to increase the participa-
tion of minority physicians in the conduct of clinical trials.
 
Table  2  presents  a  summary  of  the  disparity-specific 
themes and third-party coverage laws in each of the 55 
CCC plans that mentioned clinical trials. The Texas CCC 
plan included the most theme areas (n = 7), but Texas did 
not have a third-party coverage law. Delaware, Indiana, 
and  Oklahoma  each  covered  5  theme  areas,  but  only 
Delaware had a coverage law. More than half of the 39 
CCC  plans  that  specifically  addressed  clinical  trial  dis-
parities included the themes “increasing participation” (n 
= 24) or “education, awareness, and outreach” for under-
represented groups (n = 20); 12 plans included both these 
themes. Among the 39 disparity-specific CCC plans, 13 
were  in  states  with  a  third-party  reimbursement  law. 
The “education, awareness, and outreach” theme and the 
“availability  of  trials”  theme  surfaced  in  all  4  tribal  or 
territory CCC plans. The themes “culturally appropriate 
information,” “financial support,” and “funding” were the 
least frequently mentioned among the plans. No pattern 
appeared to exist between the dates of a plan and whether 
it mentioned a specific theme.
 
Among plans addressing the topic of disparities, some 
had a focus on specific cancers or underrepresented groups. 
Four plans mentioned a focus on a specific cancer: Arizona 
(prostate), California (lung, oral), New Hampshire (lung), 
and New Jersey (prostate). Table 3 highlights which plans 
mentioned a specific underrepresented group.VOLUME 6: NO. 4
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Discussion
 
Nearly all of the CCC plans we identified addressed clin-
ical trials in general, and most specifically addressed dis-
parities in clinical trials. The themes most often addressed 
were  increasing  the  number  of  underrepresented  par-
ticipants in clinical trials and education, awareness, and 
outreach. In general, themes that emerged were related to 
barriers that have been documented in the literature. For 
example, education, awareness, and outreach corresponds 
to the consistently reported barrier that many patients are 
unaware of clinical trials (10,12). The lack of available tri-
als has been cited as a barrier, particularly among patients 
in rural communities (18). These correspondences suggest 
that CCC planners are aware of existing barriers and are 
proposing strategies to directly address those barriers.
 
Although not having health insurance coverage is often 
a barrier to participating in clinical trials (5,6), even those 
with insurance coverage sometimes forgo participating in 
clinical trials because they fear their health insurance will 
not reimburse them (19). One study found that even after 
reimbursement laws were in place, clinical trial participa-
tion significantly increased for NCI phase II cooperative 
group trials but not for phase III (20). Conversely, another 
study found no increase in participation but did report that 
insurance type was no longer a significant factor in deter-
mining whether patients would enroll in cancer trials fol-
lowing mandatory third-party reimbursement legislation 
(21). These studies highlight the fact that reimbursement 
laws are not the lone solution to increasing participation 
in clinical trials. The comprehensive efforts reflected in 
the 10 themes that emerged in our study are examples of 
steps that may play a major role in addressing disparities 
in clinical trial participation.
 
CCC plans are at different stages of development and 
implementation. However, some CCC coalitions are already 
taking concrete steps to address clinical trial disparities. 
The  Cherokee  Nation  is  working  with  the  Oklahoma 
Society of Oncologists to facilitate access to clinical trials 
and provide information about available local trials on the 
CCC Web site (22). The Delaware Cancer Consortium has 
seen its state’s insurance code and regulations amended to 
cover cancer clinical trial participation (23). Minnesota is 
using outreach programs and community health workers 
to educate and increase awareness of clinical trials among 
racial and ethnic minorities (24). These examples suggest 
that including disparities in clinical trials as a topic in 
CCC plans would provide support for CCC coalitions and 
other local stakeholders to act on it.
 
Our findings have a few limitations. First is our keyword 
search  strategy.  Though  we  believe  our  keyword  terms 
are inclusive, we cannot assume that the remaining plans 
did not cover the themes we identified. Second, there was 
variability in CCC plan format, specifically with regard to 
level of specificity. It is likely that the more specific a plan 
was in describing its clinical trials and disparities in clini-
cal trials goals, objectives, strategies, or actions, the more 
likely we were to capture it based on our keyword search. 
Nevertheless, many of the themes that emerged from the 
information extracted from the CCC plans were consis-
tent  with  future  recommendations  from  other  sources 
(6,12). Third, the data used in this study were extracted 
from planning documents made available on the Internet. 
Therefore, we were only able to capture data that were 
posted online and not necessarily all existing data.
 
Increasing the participation of racial/ethnic and other 
underrepresented  groups  in  clinical  trials  is  a  national 
research objective (25), but to our knowledge, our study is 
the first to examine the attention given to the issue of dis-
parities in cancer clinical trials in CCC plans. CCC plans 
are a unique, publicly available resource that can serve as 
a basic indicator of how the cancer community prioritizes 
disparities  in  clinical  trials  nationally;  they  have  been 
used in previous studies on tobacco control and human 
papillomavirus (26,27). Findings from this study serve as 
a call to action to members of CCC planning coalitions and 
consortia. As a first step, if they have not identified the 
specific populations that are not appropriately represented 
in their local clinical trials, they need to identify them and 
make it a priority to correct the balance of participation. 
The next step is to prioritize the incorporation of strate-
gies for overcoming these disparities in their updated or 
revised CCC plan.
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Tables
Table 1. Summary of Themes That Emerged From Disparity-Specific Comprehensive Cancer Control (CCC) Plans (N = 39), 
United States
Theme
No. of 
Plans Definition Jurisdiction/CCC Plan Example
Participation 24 To increase the number or proportion of diverse partici-
pants in cancer clinical trials
District of Columbia: Increase the participation of eligible 
minority residents in cancer-related clinical trials by 15% by 
2010
Education, aware-
ness, and outreach
20 To provide general information about clinical trials to 
patients, the public, or other groups through various 
modes or channels
New Jersey: Educate the public regarding the purpose and 
importance of participating in clinical trials for cancer, with 
special emphasis on addressing the concerns of minority 
populations
Availability of trials 10 To increase the actual number or types of clinical trials 
for participation
New York: Increase the number of clinical trials focusing on 
cancer prevention and control in high-risk populations
Best practices 5 To use methods, processes, or techniques that are ben-
eficial to diversifying clinical trial participation
Louisiana: Distribute information about the factors that have 
led to high clinical trial enrollment rates in an indigent, pri-
marily African American population
Identifying barriers 5 To assess the specific factors that inhibit patients from 
participating in clinical trials
Arizona: Identify barriers that inhibit participation in clinical 
trials within minority populations
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Jurisdiction Plan Date
Third-Party 
Reimbursement 
Law
Total 
Disparity-
Specific 
Themes
State or area
Alabama 2006-2010 No 0
Alaska 2005-2010 No 0
Arizona 2005-200 Yes 4
Arkansas 2001-2005 No 0
California 2004-2010 Yes 4
Colorado 2005-2010 No 
Connecticut 2005-2008 Yes 1
Delaware 200-2011 Yes 5
District of Columbia 2005-2010 No 1
Florida 200-2006 No 2
Jurisdiction Plan Date
Third-Party 
Reimbursement 
Law
Total 
Disparity-
Specific 
Themes
Georgia  NA Yes 0
Hawaii 2004-2009 No 0
Idaho 2006-2010 No 1
Illinois 2005-2010 No 4
Indiana 2005-2008 No 5
Iowa 2006-2011 No 0
Kansas 2005 No 2
Kentucky NA No 0
Louisiana 2004-2009 Yes 1
Maine 2006-2010 Yes 0
Maryland 2004-2008 Yes 1
Theme
No. of 
Plans Definition Jurisdiction/CCC Plan Example
Partnerships and col-
laborations
5 To aim to develop relationships with organizations, insti-
tutions, or other groups
Oregon: Increase the enrollment of underserved populations 
in clinical trials by developing community-based partner-
ships that work with culturally diverse and underserved 
communities
Physician involve-
ment
5 To engage physicians or providers as a strategy for edu-
cating or recruiting patients to clinical trials
California: Increase the awareness of community oncologists 
of the need for participation of diverse groups in clinical tri-
als by encouraging those efforts in oncology associations
Financial support 4 To advocate for resources that aim to decrease the non-
routine costs associated with clinical trial participation 
for patients
Colorado: Develop interventions to alleviate the financial 
cost of participation in clinical trials studying treatment, sup-
portive care, and quality of life for underserved and underin-
sured cancer patients
Funding 4 To advocate for broad-level resources to address nonrou-
tine costs associated with clinical trial participation
New Mexico: Establish polices to ensure that funding is 
available for necessary follow-up care for those living in trib-
al communities who are screened for cancer through clinical 
trials and government-supported screening programs
Culturally appropriate 
information
 To explicitly state the incorporation of culturally or linguis-
tically specific information into the design or dissemina-
tion of clinical trials information
Indiana: Provide information about clinical trials in a cultur-
ally sensitive manner, including consent forms that are tai-
lored to meet the patients’ reading levels
Table 1. (continued) Summary of Themes That Emerged From Disparity-Specific Comprehensive Cancer Control (CCC) Plans 
(N = 39), United States
Table 2. Mandatory Third-Party Reimbursement Laws and Number of Disparity-Specific Themes Covered in Comprehensive 
Cancer Control Plans, by Jurisdiction (n = 55), United States 
Abbreviation: NA, not available.
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Jurisdiction Plan Date
Third-Party 
Reimbursement 
Law
Total 
Disparity-
Specific 
Themes
Massachusetts 2006-2011 Yes 0
Michigan 200 No 2
Minnesota 2005-2010 No 
Mississippi 2006-2011 No 0
Missouri 2004 Yes 2
Montana 2006-2011 No 0
Nebraska 2005 No 0
Nevada 2005 Yes 2
New Hampshire 2005 Yes 1
New Jersey 2002-200 No 
New Mexico 200-2011 Yes 2
New York 200-2010 No 
North Carolina 2001-2006 Yes 0
North Dakota 2006-2010 No 1
Ohio 2006-2010 No 1
Oklahoma 2006-2010 No 5
Oregon 2005-2010 No 
Pennsylvania 200 No 0
Rhode Island 200 Yes 0
Jurisdiction Plan Date
Third-Party 
Reimbursement 
Law
Total 
Disparity-
Specific 
Themes
South Carolina 2005-2010 No 
South Dakota 2005-2010 No 2
Tennessee 2005-2008 Yes 0
Texas 2005 No 
Utah 2006-2011 No 1
Vermont 2006-2010 Yes 0
Virginia 2001-2005 Yes 
Washington 2004-2008 No 0
West Virginia 200 Yes 1
Wisconsin 2005-2010 Yes 2
Wyoming 2006-2010 No 1
Tribe or Territory
Alaska Native Tribal 
Health Consortium
2005-2010 No 
Cherokee Nation 2005-200 No 
Northwest Portland 
Area Indian Health 
Board
200 No 
South Puget 
Intertribal Planning 
Agency
2005-2012 No 2
Table 2. Mandatory Third-Party Reimbursement Laws and Number of Disparity-Specific Themes Covered in Comprehensive 
Cancer Control Plans, by Jurisdiction (n = 55), United States 
Abbreviation: NA, not available.VOLUME 6: NO. 4
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Table 3. Underrepresented Groups Mentioned in Disparity-Specific Comprehensive Cancer Control (CCC) Plans, United States
Underrepresented Group CCC Plan
African American Arizona 
Delaware 
Louisiana 
South Carolina
Alaska Natives Alaska Native Tribal Health Consortium 
Northwest Portland Area Indian Health Board
American Indians Cherokee Nation 
Northwest Portland Area Indian Health Board
Hispanics Delaware
Low income Maryland 
West Virginia
Tribal communities New Mexico 
South Puget Intertribal Planning Agency
Uninsured or underinsured Colorado 
Maryland 
West Virginia